In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010

Executive Summary

During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
Advertisement

Related Content

Reckitt Grows Its Personal-Care Clout, Asia Footprint With $724M Paras Buy
Merck KGaA And Sanofi-Aventis To Co-Develop Cancer Drugs
FDA Issues Co-Development Guidance, But Only For Products Treating "Serious" Diseases
Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology
Financings Of The Fortnight: More IPOs But More Haircuts As Well
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale
Pfizer, Boehringer Ingelheim Tap MacroGenics In Separate Deals
Martek Plans 2011 Supplement Launches Through Amerifit Subsidiary

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel